Clario Tech | Jotup

New research highlights a significant and continued gap in achieving diversity in clinical trials of medical therapies

Retrieved on:

Wednesday, June 21, 2023

Blas, Tufts Center for the Study of Drug Development, Takeda, Clinical trial, MBA, Research, PMP, Associate, Patient, Drug development, CSDD, Shirin David, FDA, DIA, Chief sustainability officer, Pharmaceutical industry, Management, Clario Tech

PHILADELPHIA, June 21, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, and the Tufts Center for the Study of Drug Development (CSDD) will present the results of new research highlighting critical levels of under-representation by race and ethnicity in pivotal trials supporting drugs and biologics approved between 2007 and 2021.

Key Points:

Preliminary results are to be presented during the Drug Information Association (DIA) 2023 Annual Global Meeting .
Commenting on the research, Otis Johnson, Chief Diversity, Inclusion and Sustainability Officer, Clario, said, "lack of diversity in clinical trials means that the medicines, when approved, may not work for the underrepresented and could harm them.
It enables ease of trial access for a broader pool of participants with the potential to speed up trial enrollment.
It is also good for business, as the approved drugs can be confidently prescribed to a broader, more diverse patient population".

New research highlights a significant and continued gap in achieving diversity in clinical trials of medical therapies

Retrieved on:

Wednesday, June 21, 2023

PHILADELPHIA, June 21, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, and the Tufts Center for the Study of Drug Development (CSDD) will present the results of new research highlighting critical levels of under-representation by race and ethnicity in pivotal trials supporting drugs and biologics approved between 2007 and 2021.

Key Points:

Preliminary results are to be presented during the Drug Information Association (DIA) 2023 Annual Global Meeting .
Commenting on the research, Otis Johnson, Chief Diversity, Inclusion and Sustainability Officer, Clario, said, "lack of diversity in clinical trials means that the medicines, when approved, may not work for the underrepresented and could harm them.
It enables ease of trial access for a broader pool of participants with the potential to speed up trial enrollment.
It is also good for business, as the approved drugs can be confidently prescribed to a broader, more diverse patient population".

Skillz Hires Fortune 500 Legal Executive Andrew Dahlinghaus As General Counsel

Retrieved on:

Friday, June 2, 2023

Skillz (NYSE: SKLZ), the leading mobile games platform that connects players and developers through fun and fair competition, today announces that Andrew Dahlinghaus will be joining the executive team as General Counsel, effective June 26, 2023.

Key Points:

Skillz (NYSE: SKLZ), the leading mobile games platform that connects players and developers through fun and fair competition, today announces that Andrew Dahlinghaus will be joining the executive team as General Counsel, effective June 26, 2023.
“I’m excited to see how Andrew Dahlinghaus applies his background in leading legal and compliance functions at growing companies to further Skillz,” said Andrew Paradise, CEO and founder of Skillz.
In his past roles, Dahlinghaus has led best-in-class Legal and Compliance groups in Fortune 500, FTSE 250 and private equity-backed companies, including Covidien, Medtronic, and ConvaTec.
“I am thrilled to join Skillz as General Counsel at such an important time at the company,” said Dahlinghaus.

Transforming clinical trial endpoint analysis: Clario implements over 30 AI solutions to deliver faster and accurate results

Retrieved on:

Tuesday, May 23, 2023

PHILADELPHIA, May 23, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today revealed the significant progress it has made in the integration of Artificial Intelligence (AI) and Machine Learning (ML) into clinical trial data collection through their own development and strategic partnerships. Over 30 solutions have been applied, with more than half of them already active on various Clario platforms. These integrations have led to a remarkable evolution in the way clinical trial endpoint analyses are conducted at the company. By combining AI tools with deep scientific expertise, Clario is achieving faster and more accurate results than ever before. Furthermore, this integration has enhanced operational efficiencies and patient privacy protection.

Key Points:

AI and ML solutions are enhancing Clario's scientists' abilities to deliver a more efficient, accurate and faster analysis of trial participant data collection.
Clario has implemented over 30 AI solutions with more than half integrated directly into Clario platforms since 2018 through in-house development and AI-driven strategic partnerships.
By combining AI tools with deep scientific expertise, Clario is achieving faster and more accurate results than ever before.
Clario's innovation, development and implementation of multiple AI solutions for data endpoint analysis is transforming efficiency, accuracy and speed in clinical trials.

Transforming clinical trial endpoint analysis: Clario implements over 30 AI solutions to deliver faster and accurate results

Retrieved on:

Tuesday, May 23, 2023

PHILADELPHIA, May 23, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today revealed the significant progress it has made in the integration of Artificial Intelligence (AI) and Machine Learning (ML) into clinical trial data collection through their own development and strategic partnerships. Over 30 solutions have been applied, with more than half of them already active on various Clario platforms. These integrations have led to a remarkable evolution in the way clinical trial endpoint analyses are conducted at the company. By combining AI tools with deep scientific expertise, Clario is achieving faster and more accurate results than ever before. Furthermore, this integration has enhanced operational efficiencies and patient privacy protection.

Key Points:

AI and ML solutions are enhancing Clario's scientists' abilities to deliver a more efficient, accurate and faster analysis of trial participant data collection.
Clario has implemented over 30 AI solutions with more than half integrated directly into Clario platforms since 2018 through in-house development and AI-driven strategic partnerships.
By combining AI tools with deep scientific expertise, Clario is achieving faster and more accurate results than ever before.
Clario's innovation, development and implementation of multiple AI solutions for data endpoint analysis is transforming efficiency, accuracy and speed in clinical trials.

CLARIOS COMPLETES UPSIZED PRIVATE OFFERING OF $750 MILLION 6.750% SENIOR SECURED NOTES DUE 2028 AND UPSIZED $2.75 BILLION TERM LOAN FACILITY MATURING 2030

Retrieved on:

Thursday, May 4, 2023

The Company also announced the closing of a new tranche of term loans (the "New Term Loan Facility") in an aggregate principal amount of $2,750 million at SOFR plus 3.75%.

Key Points:

The Company also announced the closing of a new tranche of term loans (the "New Term Loan Facility") in an aggregate principal amount of $2,750 million at SOFR plus 3.75%.
The New Term Loan Facility will mature in May 2030.
The weighted average interest rate for the Notes and the New Term Loan Facility is expected to be approximately 7%, based on the current one-month Term SOFR swap rate for 5 years.
The gross proceeds from the offering of the Notes, together with the borrowings under the New Term Loan Facility, were used to repay approximately $3,500 million of borrowings under the Company's existing term loan facility (the "Existing Term Loan Facility") maturing in April 2026.

CNS (Central Nervous System) and Chronic Drug Trials: New Cardiac Safety Requirements, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Friday, April 28, 2023

TORONTO, Ontario, Canada, April 28, 2023 /PRNewswire-PRWeb/ -- Drugs that are chronically administered, such as those for CNS disease states, are under increased scrutiny for potential effects on cardiac safety endpoints, and for good reason. Whereas a small change in blood pressure may be inconsequential for drugs administered over a short timeframe, the story is very different for drugs that are likely to be taken for years or decades. Prolonged changes in blood pressure or QT interval are associated with a variety of patient health risks and prescribers need to carefully weigh the risks and benefits. Regulatory agencies understand this challenge and have drafted recent guidance to better detect even small changes in cardiac safety, ensuring that a drug's risk profile is well-established during development, with increased attention given to chronically administered drugs.

Key Points:

In this free webinar, learn about potential upcoming changes for cardiac safety requirements for CNS and chronically administered drugs.
TORONTO, Ontario, Canada, April 28, 2023 /PRNewswire-PRWeb/ -- Drugs that are chronically administered, such as those for CNS disease states, are under increased scrutiny for potential effects on cardiac safety endpoints, and for good reason.
For long-term CNS drugs, blood pressure evaluation has become a critical consideration to establish the potential risk for stroke or other cardiovascular diseases.
Join featured experts from Clario as they discuss the cardiac safety requirements (BP & ECG) for CNS and chronically administered drugs.

US, South Korea Sign MoU to Pave the Way for Onshoring EV Battery Production in the United States

Retrieved on:

Thursday, April 27, 2023

The signing took place at the Waldorf Astoria in Washington, DC in conjunction with US President Biden and South Korean President Yoon Suk Ye’s intergovernmental meeting.

Key Points:

The signing took place at the Waldorf Astoria in Washington, DC in conjunction with US President Biden and South Korean President Yoon Suk Ye’s intergovernmental meeting.
QAD is a member of the NAATBatt Association and QAD’s Head of EV and Mobility Andreas Bareid serves as a Co-Chairman of the NAATBatt Onshoring Committee and Board Member.
“Korean companies today are world leading experts within manufacturing of lithium based batteries,” said James Greenberger, founder and executive director of NAATBatt.
To further ensure the adoption of EV, it is critical for onshoring companies to establish production and produce the yield envisaged and required by the Inflation Reduction Act.

Global Electric Vehicle (EV) Battery Market to Grow by $53.6 Billion During 2023-2027 - ResearchAndMarkets.com

Retrieved on:

Wednesday, April 26, 2023

Technology, Batteries, EV, Electric Vehicles, Automotive, Hitachi, Clario Tech, Lithium iron phosphate battery, Research, BYD, A123 Systems, Exide Industries, EnerSys, BMS, Cummins, LG Chem, SK Innovation, Software, Retail

This study identifies the increasing use of software and sensors for intelligent BMS as one of the prime reasons driving the electric vehicle (EV) battery market growth during the next few years.

Key Points:

This study identifies the increasing use of software and sensors for intelligent BMS as one of the prime reasons driving the electric vehicle (EV) battery market growth during the next few years.
Also, EV charging with V2G technology and revision in safety standards of lithium-ion batteries will lead to sizable demand in the market.
The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

CLARIOS ANNOUNCES LAUNCH OF PRIVATE OFFERING OF NOTES

Retrieved on:

Wednesday, April 19, 2023

Straw borrower, Clario Tech, Issuer, SEC Rule 144A, Person, Sale, Prospectus, News, Regulation, Security (finance), Note

MILWAUKEE, April 19, 2023 /PRNewswire/ -- Clarios Global LP ("Clarios" or the "Company") announced today that it and Clarios US Finance Company, Inc. (the "Co-Issuer" and, together with the Company, the "Issuers"), have launched an offering of $500 million in aggregate principal amount of senior secured notes due 2028 (the "Notes").

Key Points:

MILWAUKEE, April 19, 2023 /PRNewswire/ -- Clarios Global LP ("Clarios" or the "Company") announced today that it and Clarios US Finance Company, Inc. (the "Co-Issuer" and, together with the Company, the "Issuers"), have launched an offering of $500 million in aggregate principal amount of senior secured notes due 2028 (the "Notes").
In connection with the issuance of the Notes, the Company intends to borrow up to $1,000 million under an incremental amendment (the "New Term Loan Facility") to its existing term loan facility (the "Existing Term Loan Facility").
The gross proceeds from the offering of the Notes, together with the borrowings under the New Term Loan Facility, are expected to be used to repay $1,500 million of borrowings under the Existing Term Loan Facility.
The Notes will be guaranteed by Clarios International LP, which owns all of the equity interests of the Issuers, and each of the Company's subsidiaries that are guarantors under the Company's credit agreements.